Sfoglia per Autore
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
2022-01-01 Zanghì, A; Avolio, C; Signoriello, E; Abbadessa, G; Cellerino, M; Ferraro, D; Messina, C; Barone, S; Callari, G; Tsantes, E; Sola, P; Valentino, P; Granella, F; Patti, F; Lus, G; Bonavita, S; Inglese, M; D'Amico, E.
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study
2022-01-01 Zanghì, A; D'Amico, E; Patti, F; Avolio, C.
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register
2022-01-01 Zanghì, A; Avolio, C; Amato, Mp; Filippi, M; Trojano, M; Patti, F; D'Amico, E; Italian MS, Register.
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications
2022-01-01 Zanghì, A; Avolio, C; Hartung, Hp; D'Amico, E
Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study
2022-01-01 Alvino, B.; Arianna, F.; Assunta, B.; Antonio, C.; Emanuele, A.; Giorgia, M.; Leonardo, S.; Daniele, S.; Renato, D.; Buscarinu, M. C.; Massimiliano, M.; Crisafulli, S. G.; Zanghi, Aurora.; Gabri Nicoletti, C.; Marco, S.; Viola, B.; Francesco, P.; Marfia, A. G.; Grazia, S.; Valentina, S.; Davide, O.; Giovanni, S.; Gioacchino, T.; Gallo, A.
Neural precursor cells tune striatal connectivity through the release of IGFBPL1
2022-01-01 Butti, E.; Cattaneo, S.; Bacigaluppi, M.; Cambiaghi, M.; Scotti, G. M.; Brambilla, E.; Ruffini, F.; Sferruzza, G.; Ripamonti, M.; Simeoni, F.; Cacciaguerra, L.; Zanghi, Aurora.; Quattrini, A.; Fesce, R.; Panina-Bordignon, P.; Giannese, F.; Cittaro, D.; Kuhlmann, T.; D'Adamo, P.; Rocca, M. A.; Taverna, S.; Martino, G.
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis
2022-01-01 D'Amico, E.; Zanghi, Aurora.; Parrinello, N. L.; Romano, A.; Palumbo, G. A.; Chisari, C. G.; Toscano, S.; Raimondo, F. D.; Zappia, M.; Patti, F.
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review
2023-01-01 Ciancio, A; Moretti, Mc; Natale, A; Rodolico, A; Signorelli, Ms; Petralia, A; Altamura, M; Bellomo, A; Zanghi', A; D'Amico, E; Avolio, C; Concerto, C
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study
2023-01-01 D'Amico, Emanuele; Zanghì, Aurora; Manuti, Virginia; Allegretta, Caterina; Amoruso, Antonella; Serviddio, Gaetano; Avolio, Carlo
Relapse-associated worsening in a real-life multiple sclerosis cohort: The role of age and pyramidal phenotype
2023-01-01 Zanghi', A; Bellantonio, P; Zaffaroni, M; Borriello, G; Inglese, M; Romano, S; Conte, A; Patti, F; Trojano, M; Avolio, C; D'Amico, E; Italian MS, Registry
Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study
2023-01-01 D'Amico, Emanuele; Zanghi', Aurora; Fantozzi, Roberta; Centonze, Diego; Avolio, Carlo
MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study
2023-01-01 Zanghi', A; Manuti, V; Serviddio, G; D'Amico, E; Avolio, C.
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience
2023-01-01 Zanghi', A; Ferraro, D; Callari, G; Valentino, P; Granella, F; Patti, F; Lus, G; Bonavita, S; Moretti, Mc; Avolio, C; D'Amico, E
Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey
2023-01-01 Altieri, M.; Capuano, R.; Bisecco, A.; D'Ambrosio, A.; Risi, M.; Cavalla, P.; Vercellino, M.; Annovazzi, P.; Zaffaroni, M.; De Stefano, N.; Stromillo, M. L.; D'Amico, E.; Zanghi, Aurora.; Buscarinu, M. C.; Lanzillo, R.; De Luca, G.; Calabrese, M.; Lorefice, L.; Di Filippo, M.; Valentino, P.; Gajofatto, A.; Marfia, G. A.; Fuiani, A.; Nociti, V.; Tedeschi, G.; Gallo, A.
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study
2024-01-01 Zanghi', A; Borriello, G; Bonavita, S; Fantozzi, R; Signoriello, E; Barone, S; Abbadessa, G; Cellerino, M; Ziccone, V; Miele, G; Lus, G; Valentino, P; Bucello, S; Inglese, M; Centonze, D; Avolio, C; D'Amico, E.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic | 1-gen-2022 | Zanghì, A; Avolio, C; Signoriello, E; Abbadessa, G; Cellerino, M; Ferraro, D; Messina, C; Barone, S; Callari, G; Tsantes, E; Sola, P; Valentino, P; Granella, F; Patti, F; Lus, G; Bonavita, S; Inglese, M; D'Amico, E. | |
| Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study | 1-gen-2022 | Zanghì, A; D'Amico, E; Patti, F; Avolio, C. | |
| Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register | 1-gen-2022 | Zanghì, A; Avolio, C; Amato, Mp; Filippi, M; Trojano, M; Patti, F; D'Amico, E; Italian MS, Register. | |
| Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications | 1-gen-2022 | Zanghì, A; Avolio, C; Hartung, Hp; D'Amico, E | |
| Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study | 1-gen-2022 | Alvino, B.; Arianna, F.; Assunta, B.; Antonio, C.; Emanuele, A.; Giorgia, M.; Leonardo, S.; Daniele, S.; Renato, D.; Buscarinu, M. C.; Massimiliano, M.; Crisafulli, S. G.; Zanghi, Aurora.; Gabri Nicoletti, C.; Marco, S.; Viola, B.; Francesco, P.; Marfia, A. G.; Grazia, S.; Valentina, S.; Davide, O.; Giovanni, S.; Gioacchino, T.; Gallo, A. | |
| Neural precursor cells tune striatal connectivity through the release of IGFBPL1 | 1-gen-2022 | Butti, E.; Cattaneo, S.; Bacigaluppi, M.; Cambiaghi, M.; Scotti, G. M.; Brambilla, E.; Ruffini, F.; Sferruzza, G.; Ripamonti, M.; Simeoni, F.; Cacciaguerra, L.; Zanghi, Aurora.; Quattrini, A.; Fesce, R.; Panina-Bordignon, P.; Giannese, F.; Cittaro, D.; Kuhlmann, T.; D'Adamo, P.; Rocca, M. A.; Taverna, S.; Martino, G. | |
| Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis | 1-gen-2022 | D'Amico, E.; Zanghi, Aurora.; Parrinello, N. L.; Romano, A.; Palumbo, G. A.; Chisari, C. G.; Toscano, S.; Raimondo, F. D.; Zappia, M.; Patti, F. | |
| Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review | 1-gen-2023 | Ciancio, A; Moretti, Mc; Natale, A; Rodolico, A; Signorelli, Ms; Petralia, A; Altamura, M; Bellomo, A; Zanghi', A; D'Amico, E; Avolio, C; Concerto, C | |
| MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study | 1-gen-2023 | D'Amico, Emanuele; Zanghì, Aurora; Manuti, Virginia; Allegretta, Caterina; Amoruso, Antonella; Serviddio, Gaetano; Avolio, Carlo | |
| Relapse-associated worsening in a real-life multiple sclerosis cohort: The role of age and pyramidal phenotype | 1-gen-2023 | Zanghi', A; Bellantonio, P; Zaffaroni, M; Borriello, G; Inglese, M; Romano, S; Conte, A; Patti, F; Trojano, M; Avolio, C; D'Amico, E; Italian MS, Registry | |
| Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study | 1-gen-2023 | D'Amico, Emanuele; Zanghi', Aurora; Fantozzi, Roberta; Centonze, Diego; Avolio, Carlo | |
| MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study | 1-gen-2023 | Zanghi', A; Manuti, V; Serviddio, G; D'Amico, E; Avolio, C. | |
| Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience | 1-gen-2023 | Zanghi', A; Ferraro, D; Callari, G; Valentino, P; Granella, F; Patti, F; Lus, G; Bonavita, S; Moretti, Mc; Avolio, C; D'Amico, E | |
| Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey | 1-gen-2023 | Altieri, M.; Capuano, R.; Bisecco, A.; D'Ambrosio, A.; Risi, M.; Cavalla, P.; Vercellino, M.; Annovazzi, P.; Zaffaroni, M.; De Stefano, N.; Stromillo, M. L.; D'Amico, E.; Zanghi, Aurora.; Buscarinu, M. C.; Lanzillo, R.; De Luca, G.; Calabrese, M.; Lorefice, L.; Di Filippo, M.; Valentino, P.; Gajofatto, A.; Marfia, G. A.; Fuiani, A.; Nociti, V.; Tedeschi, G.; Gallo, A. | |
| Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study | 1-gen-2024 | Zanghi', A; Borriello, G; Bonavita, S; Fantozzi, R; Signoriello, E; Barone, S; Abbadessa, G; Cellerino, M; Ziccone, V; Miele, G; Lus, G; Valentino, P; Bucello, S; Inglese, M; Centonze, D; Avolio, C; D'Amico, E. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile